[1]
|
Borén, J., Chapman, M.J., Krauss, R.M., et al. (2020) Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease: Pathophysiological, Genetic, and Therapeutic Insights: A Consensus Statement from the European Atheroscle-rosis Society Consensus Panel. European Heart Journal, 41, 2313-2330. https://doi.org/10.1093/eurheartj/ehz962
|
[2]
|
Ference, B.A., Ginsberg, H.N., Graham, I., et al. (2017) Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence from Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38, 2459-2472.
|
[3]
|
Reiner, Z. (2014) Resistance and Intolerance to Statins. Nutrition, Metabolism and Cardi-ovascular Diseases, 24, 1057-1066. https://doi.org/10.1016/j.numecd.2014.05.009
|
[4]
|
(2013) HPS2-THRIVE Randomized Placebo-Controlled Trial in 25673 High-Risk Patients of ER Niacin/Laropiprant: Trial Design, Pre-Specified Muscle and Liver Outcomes, and Reasons for Stopping Study Treatment. European Heart Journal, 34, 1279-1291. https://doi.org/10.1093/eurheartj/eht055
|
[5]
|
Giugliano, R.P. and Sabatine, M.S. (2015) Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? Journal of the American College of Cardiology, 65, 2638-2651. https://doi.org/10.1016/j.jacc.2015.05.001
|
[6]
|
王增武, 刘静, 李建军, 等. 中国血脂管理指南(2023年) [J]. 中国循环杂志, 2023, 38(3): 237-271.
|
[7]
|
Seidah, N.G., Benjannet, S., Wickham, L., et al. (2003) The Secretory Propro-tein Convertase Neural Apoptosis-Regulated Convertase 1 (NARC-1): Liver Regeneration and Neuronal Differentiation. Proceedings of the National Academy of Sciences of the United States of America, 100, 928-933. https://doi.org/10.1073/pnas.0335507100
|
[8]
|
Cuchel, M., Bruckert, E., Ginsberg, H.N., et al. (2014) Homozy-gous Familial Hypercholesterolaemia: New Insights and Guidance for Clinicians to Improve Detection and Clinical Management. A Position Paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Athero-sclerosis Society. European Heart Journal, 35, 2146-2157.
https://doi.org/10.1093/eurheartj/ehu274
|
[9]
|
Kent, S.T., Rosenson, R.S., Avery, C.L., et al. (2017) PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data from 9 Studies of Blacks and Whites. Circulation-Cardiovascular Genetics, 10, e1632. https://doi.org/10.1161/CIRCGENETICS.116.001632
|
[10]
|
Seidah, N.G. and Prat, A. (2002) Precursor Convert-ases in the Secretory Pathway, Cytosol and Extracellular Milieu. Essays in Biochemistry, 38, 79-94. https://doi.org/10.1042/bse0380079
|
[11]
|
Naureckiene, S., Ma, L., Sreekumar, K., et al. (2003) Functional Charac-terization of Narc 1, a Novel Proteinase Related to Proteinase K. Archives of Biochemistry and Biophysics, 420, 55-67. https://doi.org/10.1016/j.abb.2003.09.011
|
[12]
|
Lambert, G., Sjouke, B., Choque, B., et al. (2012) The PCSK9 Decade. Journal of Lipid Research, 53, 2515-2524.
https://doi.org/10.1194/jlr.R026658
|
[13]
|
Qian, Y.W., Schmidt, R.J., Zhang, Y., et al. (2007) Secreted PCSK9 Downregulates Low Density Lipoprotein Receptor through Receptor-Mediated Endocytosis. Journal of Lipid Research, 48, 1488-1498.
https://doi.org/10.1194/jlr.M700071-JLR200
|
[14]
|
Kwon, H.J., Lagace, T.A., McNutt, M.C., et al. (2008) Molecu-lar Basis for LDL Receptor Recognition by PCSK9. Proceedings of the National Academy of Sciences of the United States of America, 105, 1820-1825.
https://doi.org/10.1073/pnas.0712064105
|
[15]
|
Poirier, S., Mayer, G., Poupon, V., et al. (2009) Dissection of the Endogenous Cellular Pathways of PCSK9-Induced Low Density Lipoprotein Receptor Degradation: Evidence for an In-tracellular Route. Journal of Biological Chemistry, 284, 28856-28864. https://doi.org/10.1074/jbc.M109.037085
|
[16]
|
Watts, G.F., Chan, D.C., Somaratne, R., et al. (2018) Controlled Study of the Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibition with Evolocumab on Lipoprotein(a) Par-ticle Kinetics. European Heart Journal, 39, 2577-2585.
https://doi.org/10.1093/eurheartj/ehy122
|
[17]
|
Rice, L.M., Donigan, M., Yang, M., et al. (2014) Protein Phospha-tase 2A (PP2A) Regulates Low Density Lipoprotein Uptake through Regulating Sterol Response Element-Binding Pro-tein-2 (SREBP-2) DNA Binding. Journal of Biological Chemistry, 289, 17268-17279. https://doi.org/10.1074/jbc.M114.570390
|
[18]
|
Jeong, H.J., Lee, H.S., Kim, K.S., et al. (2008) Sterol-Dependent Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 Expression by Sterol-Regulatory Element Binding Protein-2. Journal of Lipid Research, 49, 399-409.
https://doi.org/10.1194/jlr.M700443-JLR200
|
[19]
|
Bedi, M., Niesen, M. and Lopez, D. (2008) Inhibition of Squa-lene Synthase Upregulates PCSK9 Expression in Rat Liver. Archives of Biochemistry and Biophysics, 470, 116-119. https://doi.org/10.1016/j.abb.2007.11.011
|
[20]
|
Rashid, S., Curtis, D.E., Garuti, R., et al. (2005) Decreased Plasma Cholesterol and Hypersensitivity to Statins in Mice Lacking Pcsk9. Proceedings of the National Academy of Sciences of the United States of America, 102, 5374-5379.
https://doi.org/10.1073/pnas.0501652102
|
[21]
|
Careskey, H.E., Davis, R.A., Alborn, W.E., et al. (2008) Atorvas-tatin Increases Human Serum Levels of Proprotein Convertase Subtilisin/Kexin Type 9. Journal of Lipid Research, 49, 394-398.
https://doi.org/10.1194/jlr.M700437-JLR200
|
[22]
|
Welder, G., Zineh, I., Pacanowski, M.A., et al. (2010) High-Dose Atorvastatin Causes a Rapid Sustained Increase in Human Serum PCSK9 and Disrupts Its Correlation with LDL Cholesterol. Journal of Lipid Research, 51, 2714-2721.
https://doi.org/10.1194/jlr.M008144
|
[23]
|
Awan, Z., Seidah, N.G., MacFadyen, J.G., et al. (2012) Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: The JUPITER Trial. Clinical Chemistry, 58, 183-189.
https://doi.org/10.1373/clinchem.2011.172932
|
[24]
|
Dias, C.S., Shaywitz, A.J., Wasserman, S.M., et al. (2012) Ef-fects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels: Results from 2 Randomized, Double-Blind, Place-bo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins. Journal of the American College of Cardiology, 60, 1888-1898.
https://doi.org/10.1016/j.jacc.2012.08.986
|
[25]
|
Keating, G.M. (2016) Evolocumab: A Review in Hyperlipidemia. American Journal of Cardiovascular Drugs, 16, 67-78. https://doi.org/10.1007/s40256-015-0153-0
|
[26]
|
Zhang, X.L., Zhu, Q.Q., Zhu, L., et al. (2015) Safety and Efficacy of Anti-PCSK9 Antibodies: A Meta-Analysis of 25 Random-ized, Controlled Trials. BMC Medicine, 13, Article No. 123. https://doi.org/10.1186/s12916-015-0358-8
|
[27]
|
O’Donoghue, M.L., Giugliano, R.P., Wiviott, S.D., et al. (2022) Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation, 146, 1109-1119.
https://doi.org/10.1161/CIRCULATIONAHA.122.061620
|
[28]
|
Kastelein, J.J., Ginsberg, H.N., Langslet, G., et al. (2015) ODYSSEY FH I and FH II: 78 Week Results with Alirocumab Treatment in 735 Patients with Heterozygous Familial Hypercholesterolaemia. European Heart Journal, 36, 2996-3003.
https://doi.org/10.1093/eurheartj/ehv370
|
[29]
|
Schwartz, G.G., Steg, P.G., Szarek, M., et al. (2018) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. The New England Journal of Medicine, 379, 2097-2107. https://doi.org/10.1056/NEJMoa1801174
|
[30]
|
Goodman, S.G., Aylward, P.E., Szarek, M., et al. (2019) Effects of Alirocumab on Cardiovascular Events after Coronary Bypass Surgery. Journal of the American College of Cardiology, 74, 1177-1186.
https://doi.org/10.1016/j.jacc.2019.07.015
|
[31]
|
Ostadal, P., Steg, P.G., Poulouin, Y., et al. (2022) Metabolic Risk Factors and Effect of Alirocumab on Cardiovascular Events after Acute Coronary Syndrome: A Post-Hoc Analysis of the Odyssey Outcomes Randomised Controlled Trial. The Lancet Diabetes & Endocrinology, 10, 330-340. https://doi.org/10.1016/S2213-8587(22)00043-2
|
[32]
|
Jukema, J.W., Zijlstra, L.E., Bhatt, D.L., et al. (2019) Effect of Alirocumab on Stroke in Odyssey Outcomes. Circulation, 140, 2054-2062. https://doi.org/10.1161/CIRCULATIONAHA.119.043826
|
[33]
|
Fitzgerald, K., Frank-Kamenetsky, M., Shul-ga-Morskaya, S., et al. (2014) Effect of an RNA Interference Drug on the Synthesis of Proprotein Convertase Subtil-isin/Kexin Type 9 (PCSK9) and the Concentration of Serum LDL Cholesterol in Healthy Volunteers: A Randomised, Single-Blind, Placebo-Controlled, Phase 1 Trial. The Lancet, 383, 60-68.
https://doi.org/10.1016/S0140-6736(13)61914-5
|
[34]
|
Lo, S.P., Bottomley, M.J., Calzetta, A., et al. (2011) Mecha-nistic Implications for LDL Receptor Degradation from the PCSK9/LDLR Structure at Neutral pH. EMBO Reports, 12, 1300-1305. https://doi.org/10.1038/embor.2011.205
|
[35]
|
Ray, K.K., Landmesser, U., Leiter, L.A., et al. (2017) In-clisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. The New England Journal of Medicine, 376, 1430-1440. https://doi.org/10.1056/NEJMoa1615758
|
[36]
|
Wright, R.S., Collins, M.G., Stoekenbroek, R.M., et al. (2020) Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clinic Proceedings, 95, 77-89.
https://doi.org/10.1016/j.mayocp.2019.08.021
|